Skip to main content
TipRanks
Go Ultimate75% OFF

Novartis AG (NOT) Drug Pipeline

23 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Cls12311 Low, Cls12311 Medium, Cls12311 High, Uncoupled RbcsRelapsing-Remitting Multiple Sclerosis (Rrms)Phase IActive Not RecruitingPeptide-coupled Red Blood Cells for the Treatment of Multiple SclerosisMay 06, 2024―
Imx-110 Combined With TislelizumabAdvanced Solid Tumorphase1AndPhase2UnknownStudy of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid TumorsJan 04, 2023―
Ribociclib, Everolimus, Alpelisib, PalazestrantBreast Cancer, Metastatic Breast Cancer, Her2-Negative Breast Cancer, Er-Positive Breast Cancer, Locally Advanced Breast CancerPhase IActive Not RecruitingPhase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, or Everolimus in ER+, HER2- Breast CancerAug 16, 2022―
Fulvestrant, Alpelisib, TucatinibHer2-Positive Metastatic Breast Cancerphase1AndPhase2RecruitingClinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Dec 27, 2021―
KetamineHealthyearlyPhase1CompletedEffects of Ketamine on ERP/EEG Measures in Healthy VolunteersMay 28, 2021―
Mrtx849, Tno155Advanced Cancer, Metastatic Cancer, Malignant Neoplastic DiseasePhase ICompletedAdagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)Mar 30, 2020―
Amg334, Oral ProphylacticEpisodic MigrainePhase IVCompletedStudy of Sustained Benefit of AMG334 in Adult Episodic Migraine PatientsApr 23, 2019―
ErenumabMigrainePhase IVTerminatedEffect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic MigraineApr 10, 2019―
Daratumumab, Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Pembrolizumab, Capecitabine, Temozolomide, Pemetrexed, Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Rucaparib, Regorafinib, Enzalutamide, SunitinibCancerPhase IIRecruitingPan Tumor Rollover StudyApr 01, 2019
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3MigrainePhase IIIActive Not RecruitingEfficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineJan 29, 2019―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Novartis (DE:NOT) have in its pipeline
Novartis AG DE:NOT is currently developing the following drugs: Cls12311 Low, Cls12311 Medium, Cls12311 High, Uncoupled Rbcs, Imx-110 Combined With Tislelizumab, Ribociclib, Everolimus, Alpelisib, Palazestrant, Fulvestrant, Alpelisib, Tucatinib, Ketamine, Mrtx849, Tno155, Amg334, Oral Prophylactic, Erenumab, Daratumumab, Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Pembrolizumab, Capecitabine, Temozolomide, Pemetrexed, Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Rucaparib, Regorafinib, Enzalutamide, Sunitinib, Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Nivolumab, Ipilimumab, Trametinib, Regorafenib, Ceritinib, T-326 Inhaler, Aggripal®, Pbf-509_80 Mg, Pbf-509_160 Mg, Pbf-509_320 Mg, Pbf-509_640 Mg, Combo Pbf-509 (160 Mg) + Pdr001, Combo Pbf-509 (320 Mg) + Pdr001, Combo Pbf-509 (640 Mg) + Pdr001, Rp2d (Pbf-509+Pdr001)_Immuno Naïve, Experimental: Rp2d (Pbf-509+Pdr001)_Immuno Treated, Ap Booster, Tdap Booster, Licensed Tdap Booster (Boostrix®), N-Acetylcysteine, Meningococcal (Group B) Multicomponent Recombinant Adsorbed Vaccine, Octreotide Fluidcrystal® Injection Depot, Diclofenac Sodium Gel 1%, Carfilzomib, Afuresertib, Rabies Vaccine, Rabies Vaccines + Rabies Immunoglobulins, Rmenb+Omv, Ciprofloxacin (Bayq3939) Dry Powder For Inhalation, Meningococcal B Recombinant Vaccine Rmenb+Omv Nz, Meningococcal Acwy-Crm Conjugate Vaccine, Bps804, Ciprofloxacin Dpi (Bayq3939), Pazopanib, Bkm120, Meningococcal Acwy Conjugate Vaccine, Depiquick Birch (Dpg103), Paracetamol (500 Mg)/Dimethindene Maleate (1 Mg)/ Phenylephrine Hydrochloride (10 Mg) Tablets, Paracetamol (500 Mg) Tablets, Menc-Crm Liq, Menc-Crm Ros, Menc-Crm Emv, Dexamethasone, Bortezomib, Gsk2110183, Bps804 20Mg/Kg, Bct197 Part A, Bct197 Part B, Prednisone, Bct197, Ruxolitinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.